Literature DB >> 16970020

Cirrhosis and chronic liver failure: part II. Complications and treatment.

Joel J Heidelbaugh1, Maryann Sherbondy.   

Abstract

Major complications of cirrhosis include ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, portal hypertension, variceal bleeding, and hepatorenal syndrome. Diagnostic studies on ascitic fluid should include a differential leukocyte count, total protein level, a serum-ascites albumin gradient, and fluid cultures. Therapy consists of sodium restriction, diuretics, and complete abstention from alcohol. Patients with ascitic fluid polymorphonuclear leukocyte counts of 250 cells per mm3 or greater should receive empiric prophylaxis against spontaneous bacterial peritonitis with cefotaxime and albumin. Patients who survive an episode of spontaneous bacterial peritonitis should receive long-term prophylaxis with norfloxacin or trimethoprim/sulfamethoxazole. Patients with gastrointestinal hemorrhage and cirrhosis should receive norfloxacin or trimethoprim/sulfamethoxazole twice daily for seven days. Treatment of hepatic encephalopathy is directed toward improving mental status levels with lactulose; protein restriction is no longer recommended. Patients with cirrhosis and evidence of gastrointestinal bleeding should undergo upper endoscopy to evaluate for varices. Endoscopic banding is the standard treatment, but sclerotherapy with vasoconstrictors (e.g., octreotide) also may be used. Prophylaxis with propranolol is recommended in patients with cirrhosis once varices have been identified. Transjugular intrahepatic portosystemic shunt has been effective in reducing portal hypertension and improving symptoms of hepatorenal syndrome, and can reduce gastrointestinal bleeding in patients with refractory variceal hemorrhage. When medical therapy for treatment of cirrhosis has failed, liver transplantation should be considered. Survival rates in transplant recipients have improved as a result of advances in immunosuppression and proper risk stratification using the Model for End-Stage Liver Disease and Child-Turcotte-Pugh scoring systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16970020

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  29 in total

1.  Ascites in patients with cirrhosis.

Authors:  Giulia-Anna Perri
Journal:  Can Fam Physician       Date:  2013-12       Impact factor: 3.275

2.  Management of liver cirrhosis between primary care and specialists.

Authors:  Ignazio Grattagliano; Enzo Ubaldi; Leonilde Bonfrate; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

Review 3.  Cirrhotic Cardiomyopathy: A New Clinical Phenotype.

Authors:  Luis Otávio Cardoso Mocarzel; Mariana Macedo Rossi; Bruna de Mello Miliosse; Pedro Gemal Lanzieri; Ronaldo Altenburg Gismondi
Journal:  Arq Bras Cardiol       Date:  2017-06       Impact factor: 2.000

Review 4.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

5.  Coexisting liver disease is associated with increased mortality after surgery for diverticular disease.

Authors:  Jonathan Montomoli; Rune Erichsen; Lisa L Strate; Lars Pedersen; Tove Nilsson; Henrik Toft Sørensen
Journal:  Dig Dis Sci       Date:  2015-01-06       Impact factor: 3.199

6.  Comparison of diagnostic accuracies of two- and three-dimensional MR elastography of the liver.

Authors:  Hiroyuki Morisaka; Utaroh Motosugi; Kevin J Glaser; Shintaro Ichikawa; Richard L Ehman; Katsuhiro Sano; Tomoaki Ichikawa; Hiroshi Onishi
Journal:  J Magn Reson Imaging       Date:  2016-09-23       Impact factor: 4.813

7.  Resource utilization and survival among Medicare patients with advanced liver disease.

Authors:  Munkhzul Otgonsuren; Linda Henry; Sharon Hunt; Chapy Venkatesan; Alita Mishra; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2014-08-10       Impact factor: 3.199

8.  Value of MR diffusion imaging in hepatic fibrosis and its correlations with serum indices.

Authors:  Xing-Rong Hu; Xian-Nian Cui; Qi-Tuo Hu; Jun Chen
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis.

Authors:  A M Walling; S C Ahluwalia; N S Wenger; M Booth; C P Roth; K Lorenz; F Kanwal; S Dy; S M Asch
Journal:  Dig Dis Sci       Date:  2016-11-01       Impact factor: 3.487

10.  Child-Turcotte-Pugh Score, MELD Score and MELD-Na Score as Predictors of Short-Term Mortality among Patients with End-Stage Liver Disease in Northern India.

Authors:  Gagandeep Acharya; Rajeev Mohan Kaushik; Rohit Gupta; Reshma Kaushik
Journal:  Inflamm Intest Dis       Date:  2019-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.